JP7728772B2 - 遺伝子発現の誘導性選択的スプライシング調節のための組成物および方法 - Google Patents

遺伝子発現の誘導性選択的スプライシング調節のための組成物および方法

Info

Publication number
JP7728772B2
JP7728772B2 JP2022548941A JP2022548941A JP7728772B2 JP 7728772 B2 JP7728772 B2 JP 7728772B2 JP 2022548941 A JP2022548941 A JP 2022548941A JP 2022548941 A JP2022548941 A JP 2022548941A JP 7728772 B2 JP7728772 B2 JP 7728772B2
Authority
JP
Japan
Prior art keywords
exon
sequence
nucleic acid
pyridazin
lmi070
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022548941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514242A (ja
JP2023514242A5 (cg-RX-API-DMAC7.html
Inventor
ビバリー エル. デービッドソン
アレハンドロ マス モンティス
アミール エイ. ハンドリー
ポール ティー. ラナム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children's Hospital of Philadelphia
Original Assignee
Children's Hospital of Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Hospital of Philadelphia filed Critical Children's Hospital of Philadelphia
Publication of JP2023514242A publication Critical patent/JP2023514242A/ja
Publication of JP2023514242A5 publication Critical patent/JP2023514242A5/ja
Application granted granted Critical
Publication of JP7728772B2 publication Critical patent/JP7728772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
JP2022548941A 2020-02-12 2021-02-12 遺伝子発現の誘導性選択的スプライシング調節のための組成物および方法 Active JP7728772B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062975400P 2020-02-12 2020-02-12
US62/975,400 2020-02-12
PCT/US2021/017950 WO2021163556A1 (en) 2020-02-12 2021-02-12 Compositions and methods for inducible alternative splicing regulation of gene expression

Publications (3)

Publication Number Publication Date
JP2023514242A JP2023514242A (ja) 2023-04-05
JP2023514242A5 JP2023514242A5 (cg-RX-API-DMAC7.html) 2024-02-21
JP7728772B2 true JP7728772B2 (ja) 2025-08-25

Family

ID=77292961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548941A Active JP7728772B2 (ja) 2020-02-12 2021-02-12 遺伝子発現の誘導性選択的スプライシング調節のための組成物および方法

Country Status (9)

Country Link
US (1) US20230340498A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103717A4 (cg-RX-API-DMAC7.html)
JP (1) JP7728772B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220146501A (cg-RX-API-DMAC7.html)
CN (1) CN115605596A (cg-RX-API-DMAC7.html)
AU (1) AU2021218807A1 (cg-RX-API-DMAC7.html)
CA (1) CA3167836A1 (cg-RX-API-DMAC7.html)
IL (1) IL295542A (cg-RX-API-DMAC7.html)
WO (1) WO2021163556A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210355509A1 (en) * 2018-08-07 2021-11-18 The Children's Hospital Of Philadelphia Alternative splicing regulation of gene expression and therapeutic methods
CN115023242B (zh) 2019-11-22 2025-03-14 费城儿童医院 腺相关病毒载体变体
WO2023054573A1 (ja) * 2021-09-30 2023-04-06 国立大学法人大阪大学 相同染色体の一方に特異的なdna欠失を有する細胞を製造する方法
US20250346893A1 (en) * 2021-10-22 2025-11-13 Fred Hutchinson Cancer Center Synthetic introns for targeted gene expression
CA3254228A1 (en) 2022-05-18 2023-11-23 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS FOR REGULATING INDUCIBLE ALTERNATIVE SPLICING OF GENE EXPRESSION
WO2024060205A1 (zh) * 2022-09-23 2024-03-28 北京基驭医疗科技有限公司 包含基于小分子药物的可变剪接调节元件的核酸分子
WO2024118610A2 (en) * 2022-11-28 2024-06-06 Siren Biotechnology, Inc. Gene therapy vectors for treatment of cancer
WO2024173699A2 (en) * 2023-02-16 2024-08-22 Mammoth Biosciences, Inc. Compositions for the treatment of spinal muscular atrophy
WO2024186892A2 (en) * 2023-03-06 2024-09-12 The Children's Hospital Of Philadelphia Regulated control of rna interference by alternative splicing
EP4701634A1 (en) 2023-04-28 2026-03-04 Kriya Therapeutics, Inc. Riboswitches for regulating gene expression and therapeutic methods of using the same
AU2024286618A1 (en) 2023-06-09 2025-10-30 F. Hoffmann-La Roche Ag Inducible gene expression system
WO2026125303A1 (en) 2024-12-11 2026-06-18 F. Hoffmann-La Roche Ag Inducible gene expression system

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
JP2015508075A (ja) 2012-02-10 2015-03-16 ピーティーシー セラピューティクス, インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
WO2020033473A1 (en) 2018-08-07 2020-02-13 The Children's Hospital Of Philadelphia Alternative splicing regulation of gene expression and therapeutic methods
WO2021014428A1 (en) 2019-07-25 2021-01-28 Novartis Ag Regulatable expression systems

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838657B2 (en) * 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
GB2443186A (en) * 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
HUE047898T2 (hu) * 2013-10-28 2020-05-28 Invectys Telomerázt kódoló DNS vakcina
CN108603230A (zh) * 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
JP2019535789A (ja) * 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
WO2022204471A1 (en) * 2021-03-26 2022-09-29 Ptc Therapeutics Inc. Regulation of transgene expression using a small molecule inducible splicing switch
CN118480543A (zh) * 2024-03-01 2024-08-13 五邑大学 一种可变剪接调节元件及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
JP2015508075A (ja) 2012-02-10 2015-03-16 ピーティーシー セラピューティクス, インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
WO2020033473A1 (en) 2018-08-07 2020-02-13 The Children's Hospital Of Philadelphia Alternative splicing regulation of gene expression and therapeutic methods
WO2021014428A1 (en) 2019-07-25 2021-01-28 Novartis Ag Regulatable expression systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE CHEMICAL BIOLOGY,2015年,Vol.11, No.7,pp.511-517

Also Published As

Publication number Publication date
WO2021163556A1 (en) 2021-08-19
CN115605596A (zh) 2023-01-13
JP2023514242A (ja) 2023-04-05
US20230340498A1 (en) 2023-10-26
EP4103717A4 (en) 2024-02-28
CA3167836A1 (en) 2021-08-19
IL295542A (en) 2022-10-01
EP4103717A1 (en) 2022-12-21
KR20220146501A (ko) 2022-11-01
AU2021218807A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
JP7615021B2 (ja) 遺伝子発現の選択的スプライシング調節および治療方法
US20230340498A1 (en) Compositions and methods for inducible alternative splicing regulation of gene expression
US20240100194A1 (en) Adeno-associated viral vector variants
US12383615B2 (en) Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
TW202334194A (zh) 用於表現因子ix以便治療b型血友病的組成物及方法
KR20250031153A (ko) 뇌 심부 구조를 표적화하기 위한 아데노-관련 바이러스 벡터
WO2024186892A2 (en) Regulated control of rna interference by alternative splicing
US20250303000A1 (en) Compositions and methods for inducible alternative splicing regulation of gene expression
KR20250011923A (ko) 뇌 미세혈관을 표적화하기 위한 아데노 관련 바이러스 벡터
HK40048158A (en) Alternative splicing regulation of gene expression and therapeutic methods
RU2845941C1 (ru) Варианты аденоассоциированного вирусного вектора
US20240156873A1 (en) Methods to genetically engineer hematopoietic stem and progenitor cells for red cell specific expression of therapeutic proteins
TW202604549A (zh) 基因治療劑之剖析
RU2811724C2 (ru) РЕДАКТИРОВАНИЕ ГЕНОВ С ИСПОЛЬЗОВАНИЕМ МОДИФИЦИРОВАННОЙ ДНК С ЗАМКНУТЫМИ КОНЦАМИ (зкДНК)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221110

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250717

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250813

R150 Certificate of patent or registration of utility model

Ref document number: 7728772

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150